CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · Real-Time Price · USD
0.970
+0.070 (7.78%)
Apr 29, 2026, 12:02 PM EDT - Market open
CytoMed Therapeutics Employees
CytoMed Therapeutics had 43 employees as of December 31, 2024. The number of employees increased by 9 or 26.47% compared to the previous year.
Employees
43
Change (1Y)
9
Growth (1Y)
26.47%
Revenue / Employee
$15,565
Profits / Employee
-$71,969
Market Cap
11.48M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 43 | 9 | 26.47% |
| Dec 31, 2023 | 34 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Lunai Bioworks | 29 |
| Imunon | 25 |
| BioCardia | 21 |
| Reviva Pharmaceuticals Holdings | 14 |
| BioVie | 13 |
| Cellectar Biosciences | 11 |
| Traws Pharma | 7 |
| Enveric Biosciences | 6 |
GDTC News
- 7 months ago - CytoMed Therapeutics Earnings Call Transcript: H1 2025 - Transcripts
- 7 months ago - CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia - GlobeNewsWire
- 8 months ago - Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition - GlobeNewsWire
- 9 months ago - CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program - GlobeNewsWire
- 10 months ago - Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - GlobeNewsWire
- 1 year ago - CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates - GlobeNewsWire
- 1 year ago - CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders - GlobeNewsWire
- 1 year ago - Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor - Benzinga